

Resource Summary Report

Generated by [PRECISE-TBI](#) on Sep 8, 2026

PharmGKB

RRID:SCR_002689

Type: Tool

Proper Citation

PharmGKB (RRID:SCR_002689)

Resource Information

URL: <http://www.pharmgkb.org/>

Proper Citation: PharmGKB (RRID:SCR_002689)

Description: Database and central repository for genetic, genomic, molecular and cellular phenotype data and clinical information about people who have participated in pharmacogenomics research studies. The data includes, but is not limited to, clinical and basic pharmacokinetic and pharmacogenomic research in the cardiovascular, pulmonary, cancer, pathways, metabolic and transporter domains. PharmGKB welcomes submissions of primary data from all research into genes and genetic variation and their effects on drug and disease phenotypes. PharmGKB collects, encodes, and disseminates knowledge about the impact of human genetic variations on drug response. They curate primary genotype and phenotype data, annotate gene variants and gene-drug-disease relationships via literature review, and summarize important PGx genes and drug pathways. PharmGKB is part of the NIH Pharmacogenomics Research Network (PGRN), a nationwide collaborative research consortium. Its aim is to aid researchers in understanding how genetic variation among individuals contributes to differences in reactions to drugs. A selected subset of data from PharmGKB is accessible via a SOAP interface. Downloaded data is available for individual research purposes only. Drugs with pharmacogenomic information in the context of FDA-approved drug labels are cataloged and drugs with mounting pharmacogenomic evidence are listed.

Abbreviations: PharmGKB

Synonyms: Pharmacogenomics Knowledge Base

Resource Type: data access protocol, data or information resource, data repository, data set, database, service resource, software resource, storage service resource, web service

Defining Citation: [PMID:11908751](#)

Keywords: pharmacogenomics, microarray, pathway, phenotype, snp array, genotype, clinical, genetic variation, drug, gene, genetic variation, disease, cardiovascular,

pulmonary, cancer, metabolic, transporter, drug response, small molecule, research, drug response, FASEB list

Funding: NIGMS R24 GM61374

Availability: Free, Freely available

Resource Name: PharmGKB

Resource ID: SCR_002689

Alternate IDs: nif-0000-00414, OMICS_01586, r3d100012325

Alternate URLs: <https://doi.org/10.17616/R31H1N>

License: Creative Commons Attribution-Sharealike License, v4

Record Creation Time: 20220129T080214+0000

Record Last Update: 20260905T132452+0000

Ratings and Alerts

No rating or validation information has been found for PharmGKB.

No alerts have been found for PharmGKB.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1276 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Cai L, et al. (2026) Hydrogel microspheres loaded with sinomenine and Drynaria rhizome enhance the treatment of rheumatoid arthritis via immune regulation and promoting bone repair. *Journal of nanobiotechnology*, 24(1), 174.

Yan H, et al. (2026) miR-376c-3p mediates icariin's anti-osteoclastogenic effect by targeting Mmp3. *Journal of orthopaedic surgery and research*, 21(1), 80.

Mokbel K, et al. (2026) Evaluating genotype-treatment interactions for high-risk medications in British general practice: a retrospective cohort study using UK Biobank. *The British journal of general practice : the journal of the Royal College of General Practitioners*, 76(763), e163.

Tremmel R, et al. (2026) Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-

Up. Clinical pharmacology and therapeutics, 119(1), 241.

Olivier IS, et al. (2026) Personalized care of paediatric drug-resistant epilepsy in Africa: A single-centre pilot study utilizing mobile health and genetic testing. Developmental medicine and child neurology, 68(3), 394.

Liang J, et al. (2026) Pharmacogenomics-guided personalized medicine in a clinical setting: real-world data. Pharmacogenetics and genomics, 36(2), 56.

Huang T, et al. (2026) Explainable drug side effect prediction in central neural system via biologically informed graph neural network. Translational psychiatry, 16(1).

Hajto J, et al. (2026) Computational variant predictors for pharmacogenomics: from evaluation of single alleles to assessment of adverse drug reactions to antidepressants. The pharmacogenomics journal, 26(2).

Liu P, et al. (2026) Exploring the toxicological effects of Di-O-benzoyldiethylene glycol plasticizer on allergic rhinitis through network toxicology combined with molecular docking and molecular simulation. Scientific reports, 16(1).

Tang W, et al. (2026) Targeting cell membrane sphingolipids: a novel ceramide analog CeY-B1 inhibits migration and invasion in cervical cancer cells. Journal of translational medicine, 24(1).

Khan I, et al. (2026) Systems Analysis of miRNA-Mediated Host Regulatory Response in HPV-Associated Cervical Malignancy. Computational and structural biotechnology journal, 35(1), 0031.

He X, et al. (2026) Integration of bioinformatics analysis and experimental verification reveals the role of neutrophil extracellular traps in silica nanoparticles-induced lung injury. Journal of nanobiotechnology, 24(1).

Wang Y, et al. (2026) Integrative bioinformatics, network toxicology, and molecular docking elucidate molecular mechanisms of ATBC-induced sarcoma progression with experimental validation. BMC pharmacology & toxicology, 27(1).

Llaurad-Pont J, et al. (2026) Maternal Chrono-Nutrition and Placental DNA Methylation: The BiSC Study. Molecular nutrition & food research, 70(9), e70465.

Mouton M, et al. (2026) Pharmacogenetics of Mycophenolic Acid in Patients of African Descent: Underrepresentation of African Data. Clinical and translational science, 19(5), e70599.

Al-Damook N, et al. (2026) Mapping metabolic reprogramming in lung and breast cancer through integrative bioinformatics. PloS one, 21(6), e0350628.

Jiang H, et al. (2026) A study on the effects of garlic residue-jujube complex on antioxidant capacity, intestinal microbiota, and meat quality of meat ducks. Poultry science, 105(9), 107195.

Robertson SP, et al. (2026) A primary care pharmacogenetic precision medicine pilot based on specific Mori tribal ethical frameworks and principles. Journal of community

genetics, 17(4).

Mlcuchova N, et al. (2026) Transporter gene variants influencing metformin pharmacokinetics and pharmacodynamics common in European populations: a pharmacogenetic narrative review. *Frontiers in pharmacology*, 17, 1794405.

Zhu Y, et al. (2026) Optimization strategies for voriconazole dosing in pediatric populations: integrating therapeutic indications and age-stratified pharmacokinetics. *Antimicrobial agents and chemotherapy*, 70(3), e0116925.